Incidence of second primary tumours among childhood cancer survivors. by Hawkins, M. M. et al.
Br. J. Cancer (1987), 56, 339 347 © The Macmillan Press Ltd., 1987~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Incidence of second primary tumours among childhood cancer survivors
M.M. Hawkins, G.J. Draper & J.E. Kingston
Childhood Cancer Research Group, Radcliffe Infirmary, Oxford OX2 6HE, UK.
Summary Among a cohort of 10,106 three-year survivors of childhood cancer, 90 second primary tumours
(SPTs) were observed. Within 25 years of 3-year survival about 4% developed a SPT, about 6-fold expected,
the relative risk not varying much with increasing follow-up.
Following genetic retinoblastoma we observed 30-fold the expected number of SPTs, and over 400-fold the
expected number of osteosarcomas. The risk of SPT in the absence of radiotherapy and chemotherapy
(inherent risk) following genetic retinoblastoma was 13-fold expected and over 200-fold the expected number
of osteosarcomas were observed. There was evidence that both radiotherapy and cyclophosphamide were
associated with an increased risk of SPT.
After all first primary tumours (FPTs) excluding retinoblastoma we observed almost 5-fold the expected
number of SPTs. The inherent risk was 4-fold expected, the relative risks associated with radiotherapy but no
chemotherapy, and both radiotherapy and chemotherapy were 6- and 9-fold expected respectively. There were
about 20-fold the number of malignant bone tumours expected, most were osteosarcoma; also 7-fold the
number of central nervous system tumours expected. There were 8 basal cell carcinomas and it seems likely
that radiotherapy was involved in the development of some of these. Radiotherapy appears to have been
involved in the development of many of the SPTs observed following all FPTs excluding retinoblastoma,
particularly after CNS tumours, Wilms' tumour and Hodgkin's disease. Currently there is insufficient follow-
up to examine the risk following chemotherapy. After acute leukaemia there was 20-fold the expected number
of central nervous system tumours, though this is based on only 3 cases; whether therapy is directly involved
in their development is uncertain.
The risks we report are rarely greater than those reported in previous large-scale studies; in most instances
they are substantially less. It is very unlikely that many SPTs were missed with our follow-up system so
alternative explanations require further investigation; in particular it is possible the lower risks in our data
compared to series treated in the United States may be explained, in part, by less combination therapy and
lower doses of radiotherapy.
At least half of the children who develop cancer now survive
beyond three years (Stiller, pers. comm.); thus we expect in
excess of 600 such survivors each year from among
individuals currently treated in Britain. The intensive therapy
given to achieve the improvement in survival contributes
towards late effects generally, and second primary tumours
in particular. The duration of survival for many individuals
includes the latent periods characteristic of radiation and
chemical carcinogenesis (Boice, 1981; Committee on the
Biological Effects of Ionizing Radiation, 1980; International
Agency for Research on Cancer, 1981; Schmahl et al., 1982).
Furthermore since individuals are initially treated when
young there is less opportunity for other environmental
factors to be important in the development of second
tumours.
We examine the incidence of second primary tumours
(SPTs) within a well defined cohort of three-year survivors
of childhood cancer treated in Britain between 1940 and
1979. In the accompanying paper (Kingston et al., 1987) we
examine the relationship between first and second primary
tumours in our complete register of multiple primary tumour
cases, all of whom developed at least two distinct primary
tumours, at least one of these being diagnosed before age 15;
this group includes cases excluded from the cohort.
Materials and methods
Ascertainment ofcases
The Childhood Cancer Research Group (CCRG), in Oxford,
is notified of all tumours registered under the national
cancer registration scheme occurring in individuals aged
under 15 and diagnosed in 1962 or later. This provides,
within the limits of completeness of registration, a
population based series of childhood cancer cases in Britain.
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Childhood cancer registration is estimated to include over
90% of incident cases (Stiller, 1985; Draper et al., 1982). In
addition a series of three-year survivors diagnosed before
1962 was constructed from case-lists, when they were known
to be complete, covering specific years of diagnosis at
particular registries or treatment centres, extending back to
1940 for some centres. There are just under 2,000 such three-
year survivors included among the total of about 10,000.
Cases were selected if diagnosed in 1979 or earlier and
routinely ascertained, as above, through their first primary
tumour (FPT). Follow-up with respect to SPT was achieved
by 'flagging' almost all survivors at the National Health
Service Central Registers, and through the routine receipt of
cancer registrations below age 15. 'Flagging' an individual at
NHSCR ensures the automatic notification of deaths
registered at any time and of cancer registrations from 1971
onwards. In addition, positive medical follow-up was
available for most cases through hospital records, general
practitioners and cancer registries. Furthermore, all death
certificates for deaths from neoplasia occurring before age 20
in Britain are received by the CCRG and routinely checked
for evidence of multiple tumours. The study end-point for
almost all cases not dying, emigrating or lost to follow-up
was 31 December 1981. For the remainder the study end-
point was the most recent date available through positive
follow-up or the routine receipt of cancer registrations below
age 15. SPTs were included in the incidence calculations
provided they occurred before the study end-point.
Confirmation that very few second primary tumours have
been missed is provided by a separate study that involved
writing to the general practitioners of 2,000 of the surviving
cases in the present study and asking specifically about other
primary tumours. No additional SPTs were identified by this
independent study. We restrict attention to the incidence of
SPTs among three-year survivors; this excludes the three
years immediately after diagnosis when therapeutic influences
are less likely to contribute towards the development of a
subsequent tumour, and where recurrence and metastatic
spread are much more common.
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In general, both the first and second primary tumour were
required to be malignant or intracranial to be included.
However, non-melanoma malignant skin tumours were
excluded from the relative risk calculations because of the
known incompleteness of ascertainment in the general
population and the suspected substantially better ascertain-
ment among cases already having suffered a FPT. When an
individual is suspected to have had multiple primary
tumours the diagnoses of both the first and second tumours
have, in over 90% of cases, been confirmed by review of
the relevant pathological material. For a few cases, almost
always brain tumours or retinoblastoma, where no histo-
logical material was available, confirmation of the diagnosis
was based on a review of radiological or clinical evidence
or both.
For tumours other than retinoblastoma treatment
information was obtained from hospital and general
practitioner records when readily available, but was only
obtained in relation to initial treatment. Therefore treatment
information for recurrence occurring a substantial time after
initial treatment will have been missed.
Statistical methods
The method used to compare the observed number of
subsequent primaries with those expected was based on the
assumption that the observed number of second primaries
approximated a Poisson distribution. Test of significance and
confidence intervals for the relative risk of a SPT were based
on exact Poisson probabilities since the numbers of events
are small. Expected numbers of subsequent cancers were
estimated by applying age/sex specific rates derived from
cancer registration statistics (Office of Population Censuses
and Surveys, 1983) to the person-years accumulated in the
corresponding age/sex specific categories. The cumulative
probability of a second primary tumour was estimated using
standard Kaplan-Meier procedures described by Peto et al.
(1977); comparison of the cumulative risks of SPT for
different subgroups was carried out using standard tests
(Peto et al., 1977).
A measure of inherent risk was based on SPTs occurring
among all individuals treated with neither radiotherapy nor
chemotherapy; it is therefore a measure of the risk of SPT in
the absence of radiotherapy or chemotherapy. It is possible
that those selected for radiotherapy or chemotherapy with a
particular tumour are more prone to SPTs than those not so
treated. It is impossible to examine this possibility with the
present data.
Results
Classification oftumours
A total of 10,106 cases satisfied all criteria required for
inclusion as a FPT; 90 of these developed a second primary
tumour satisfying all conditions necessary for inclusion in
incidence estimates. A cross-tabulation of the SPT cases is
given in Table I; the rows correspond to different FPT
groups classified according to morphology (World Health
Organisation, 1976). The columns correspond to the different
SPT groups classified firstly by site of tumour (World Health
Organisation, 1969), and secondly classified by morphology.
The extreme right hand column of Table I gives the total
number of three-year survivors at risk of a SPT after each
initial tumour type.
The comparison with expected incidence is restricted to
SPTs with an ICD-8 code within the range (140-209) since
this is the range where adequate general population
registration figures are available. This excludes six SPTs
given in Table I from the relative risk estimates; in addition
to the non-melanoma malignant skin neoplasms.
SPTs after all initial tumour types
Of the 10,106 three-year survivors 7,871 were followed up to
the end-point of the study, 31 December 1981; 2,235 were
either censored (death, emigration or lost to follow-up) or
were diagnosed with a SPT before the study end-point. For
six of these cases no follow-up was available.
The estimates of relative risk of a second tumour after all
FPTs considered together are given in Table II. A total of
78,483 person-years at risk were accumulated, and the
average follow-up from three-year survival was 7.8 years.
During this period 76 SPTs satisfying inclusion criteria were
observed, 13 expected, yielding a relative risk about 6. The
highest relative risk was for bone tumours with a relative
risk of 43, and an associated 95% confidence interval from
29 to 63. In what follows similar statements are abbreviated
to (RR=43, 95%CI==29, 63). This was followed by, in
decreasing order of estimated relative risk: connective tissue
(RR=15, 95%CI=5,33); thyroid (RR=14, 95%CI=3,41);
digestive system (RR= 10, 95%CI =5,20) and the CNS
(RR=7, 95%CI=4, 12). The relative risk for leukaemia was
3.2 (95%CI = 1.2, 7.0).
The estimated cumulative probability of a second primary
within 25 years of three-year survival was estimated to be
3.7% (SE=0.6%); excluding the non-melanoma skin cancer
the risk was 3.3% (SE=0.6%).
Variation in the excess risk of a SPT in relation to time
elapsed from diagnosis is given in Table III. There is no
clear systematic variation in relative risk with time survived,
in particular there is no evidence of any substantial decrease
30 years from diagnosis. The additive excess is increasing as
a consequence of an approximately constant relative risk and
the general population rate of cancer increasing with follow-
up.
SPTs after retinoblastoma
We classify unilateral cases known to be familial and
bilateral cases as 'genetic', unilateral cases with no evidence
of family history as 'non-genetic'. In contrast to the
generality of cases included in the cohort, individuals with
retinoblastoma have been followed-up much more
intensively, since they have formed the basis of a separate
detailed study (Draper et al., 1986), and as a result we know
whether radiotherapy or chemotherapy was given, at any
time, for almost all cases. The majority of second primaries
were osteosarcoma. Among the 366 genetic cases 23 SPTs
developed; in contrast there were four SPTs among the 455
non-genetic cases.
SPTs after genetic retinoblastoma
Overall risk of SPTs The estimated cumulative risk of a
SPT twenty years from three-year survival following genetic
retinoblastoma was 7.9%. The percentage developing an
osteosarcoma over a similar period was 6.0%. The relative
risk of a malignant SPT was (RR=29, 95%CI= 18, 43) the
relative risk of a malignant bone tumour was (RR=415,
95%CI=232,686); the mean follow-up period underlying
these relative risks was 13.7 years. Since all the observed
bone tumours were osteosarcomas, the relative risk of an
osteosarcoma is much greater than 400. The relative risks of
a subsequent connective tissue or central nervous system
tumour were (RR= 130, 95%CI=27, 379) and (RR= 17,
95%CI =2, 62) respectively.
Risk of SPT in relation to treatment Among survivors
receiving neither radiotherapy nor chemotherapy almost 3%
developed a SPT within 15 years of three-year survival. The
observed number of malignant SPTs was thirteen-fold
expected; almost 200-fold the expected number of malignant
bone tumours were observed. Details of the risks of a SPT
after genetic retinoblastoma, both inherent and treatment
associated, are given in Table IV. There was evidence of anSECOND PRIMARY TUMOURS AFTER CHILDHOOD CANCER 341
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Table II Observed and expected SPTs among all three-year
survivors
TOTAL
No. in group 10,100
Person-years 78,483
Mean follow-up (years)a 7.8
SPT (ICD-8) 0 E O/E 95%CI
All sites (140-209)b 76 13.06 5.8 (4.6, 7.2)
Digestive (150-159) 9 0.87 10.3 (4.7, 19.6)
Bone (170) 28 0.65 43.3 (28.9, 62.6)
Connective tissue (171) 6 0.40 15.1 (5.5, 32.8)
Breast (174) 3 1.06 2.8 (0.6, 8.2)
Genito-urinary (180-189) 5 2.40 2.1 (0.7, 4.9)
CNS (191-192) 12 1.72 7.0 (3.6, 12.2)
Thyroid (193) 3 0.21 14.1 (2.9, 41.2)
Leukaemia (204-207) 6 1.87 3.2 (1.2, 7.0)
aIn this table and in all subsequent tables where mean follow-up
intervals are quoted they exclude the initial 3 years all subjects need
to survive to be included in the present study; bIn this table and all
subsequent tables providing relative risks for 'all sites', non-
melanoma malignant skin tumours are excluded from both observed
and expected numbers.
increased risk of SPTs generally and osteosarcoma in
particular following radiotherapy without chemotherapy
compared to that following neither radiotherapy nor chemo-
therapy. Furthermore there is suggestive evidence that the
risks of SPTs generally, and osteosarcoma in particular, are
increased following radiotherapy and chemotherapy (almost
always cyclophosphamide in this series) compared to those
given radiotherapy but no chemotherapy. However, cases
given chemotherapy were also more likely to have had more
than one course of radiotherapy and radioactive implants.
Thus although there is some evidence of an increased risk of
SPT associated with the use of cyclophosphamide, this may
be due to cyclophosphamide, radiotherapy or an interaction
between them. For a more detailed examination of the
associations between risk of SPT and therapy the reader
should consult our more detailed papers on retinoblastoma
(Draper et al., 1986; Hawkins, 1987).
SPTs after all FPTs except retinoblastoma
For the sub-cohort of all FPTs except retinoblastoma we
give, in Table V, the numbers of three-year survivors at risk
following treatment with radiotherapy, chemotherapy, both
and neither of these forms of therapy. Two important
considerations are illustrated by Table V.
Table V Treatment given for FPTs other than retinoblastoma
No. SPTs
No. No. Inside/edge No. of
at risk SPTs RTfleld SPT leuks.
RT or CH no record 1,656 1 0 0
Neither RT nor CH 1,495 10 - 0
RT but no CH 2,668 40 26 3
CH but no RT 767 1 - 0
Both RT and CH 2,699 11 6 3
9,285 63 32 6
Firstly there is a relatively small number of SPTs after
chemotherapy and thus we are unable to examine the risk of
SPT associated with chemotherapy in much detail following
specific FPTs. This arises from the relatively recent
widespread use of chemotherapy, and, given the current
study end-point, average follow-up times are short. The
mean follow-up times beyond three years for those having
received neither radiotherapy nor chemotherapy, radio-
therapy but no chemotherapy and both radiotherapy and
chemotherapy following FPTs other than retinoblastoma
were 9.5, 9.8 and 3.8 years respectively (see Table VII).
The second general point illustrated by Table V follows
from the large category of cases with no record of whether
radiotherapy or chemotherapy were given. Comparisons
between different treatment subgroups must be undertaken
carefully since the records of a patient who develops a SPT
are pursued with much greater effort than are those for
cohort members not developing a SPT; as a result we know
the details with regard to both radiotherapy and chemo-
therapy for all but one of the patients developing a SPT.
Table III Excess risk of SPT at varying times from diagnosis
Completed yearsfrom diagnosis
3-4 5-9 10-14 15-19 20-24 25-29 30-
Person-years (PY) 17,961 27,995 16,237 9,350 4,580 1,650 710
Observed SPTs (0) 9 25 17 8 6 6 5
Expected SPTs (E) 1.8 3.1 2.5 2.2 1.6 0.9 0.9
Relative risk (O/E) 4.9 8.0 6.8 3.6 3.7 6.8 5.7
Additive excess risk
[(O-E)/PY] 1000 0.4 0.8 0.9 0.6 1.0 3.1 5.8
Table IV Risk of SPT after genetic retinoblastoma - Association with treatment
Mean SPT % with SPT by 15yrs
Treatment follow-up from 3-year survival
group No. period (yrs) Type No.a (standard error) ob E O/E 95%CI
Neither 60 13.4 all 2 2.7% (3.3%) 2 0.15 13 (2, 47)
RT nor CH bone 1 2.7% (3.3%) 1 0.01 174 (4, 965)
RT but no CH 241 13.8 all 13 6.8% (2.5%) 13 0.49 26 (14, 45)
bone 8 5.2% (2.2%) 8 0.02 340 (146, 668)
Both RT 62 13.5 all 7 13.3% (5.8%) 7 0.09 78 (31, 160)
and CH bone 5 9.2% (5.0%) 5 0.01 771 (250, 1802)
aTotal number of SPTs observed; bTotal number of observed SPTs eligible for inclusion in the relative risk.SECOND PRIMARY TUMOURS AFTER CHILDHOOD CANCER 343
Hence, if we analyse any group of patients for which the
treatment is known we obtain spuriously high estimates of
incidence, the amount of possible bias being determined by
the size of the 'no record' category. All subsequent analyses
were carried out separately, including and excluding the 'no-
record' category. However, we report the results of both
only when inclusion or exclusion affects the risk estimates
materially; otherwise we report the results excluding the 'no-
record' category.
Some of the individuals developing a SPT were known to
have a genetic condition known to predispose to neoplasia,
the most common condition being neurofibromatosis; there
were also some individuals with Gorlin's (basal cell naevus)
syndrome, and one from a family with Multiple Endocrine
Neoplasia type 2 (MEN2 or Sipple's syndrome). In all results
that follow we have carried out the analysis both including
and excluding these cases. We again report the results of
both analyses when inclusion or exclusion materially affected
the risk estimates, otherwise we report the risk including
these individuals.
Risk ofSPTfollowing all FPTs except retinoblastoma
Overall risk of SPT We observed almost five-fold the
number of malignant tumours expected, Table VI. The
number of malignant bone tumours observed was almost
twenty-fold expected, eight osteosarcomas being observed
among the ten malignant bone tumours. All thyroid and all
but one of the connective tissue tumours arose after a CNS
tumour and are discussed below. Almost ten-fold the
expected number of digestive tract tumours were observed.
Seven-fold the expected number of CNS tumours were
observed and four-fold the expected number of leukaemias.
The cumulative risk of a SPT by 25 years from three-year
survival was 3.7% (SE=0.8%).
Table VI Observed and expected SPTs among three-year survivors
of all FPTs except retinoblastoma
TOTAL
No. in group 9,279
Person-years 67,449
Mean follow-up (years) 7.3
SPT (ICD-8) 0 E O/E 95%CI
All sites (140-209) 50 11.20 4.5 (3.3, 5.9)
Digestive (150-159) 7 0.74 9.5 (3.8, 19.6)
Bone (170) 10 0.57 17.7 (8.5, 32.5)
Connective tissue (171) 5 0.35 14.4 (4.7, 33.7)
Breast (174) 2 0.86 2.3 (0.3, 8.4)
Genito-urinary (180-189) 4 2.08 1.9 (0.5, 4.8)
CNS (191-192) 10 1.57 6.8 (3.3, 12.5)
Thyroid (193) 3 0.19 16.0 (3.3, 46.9)
Leukaemia (204-207) 6 1.59 3.8 (1.4, 8.2)
Inherent risk of SPT By twenty years from three-year
survival among those given neither radiotherapy nor chemo-
therapy the risk of a SPT is under 2%, Table VII. This
corresponds to about four-fold the number of subsequent
malignant tumours expected. Among these individuals the
risk of a subsequent bone or CNS tumour is greater than
expected, although because of small numbers the magnitude
of the excess is subject to wide confidence limits in both
cases.
Risk of SPT in relation to radiotherapy Among those given
radiotherapy but no chemotherapy the cumulative risk of a
SPT within twenty years of three-year survival was just
under 3%, see Table VII. A comparison of the cumulative
risk of a SPT following radiotherapy but no chemotherapy
with the inherent cumulative risk revealed they were
significantly different at the P=0.02 level (one-sided test)
irrespective of inclusion or exclusion of the genetically
predisposed cases developing a SPT. Twenty-nine of the
forty SPTs arose inside or on the edge of tissue directly
irradiated to treat the FPT, this includes three second
leukaemias. Of the eleven SPTs arising outside tissue directly
irradiated four arose in individuals with neurofibromatosis.
Although specifically excluded from the relative risks there
were eight non-melanoma malignant skin tumours, all basal
cell carcinomas. All developed within tissue directly
irradiated to treat the FPT. Seven of the eight were
diagnosed more than a decade after radiotherapy for the
FPT. Among those given radiotherapy but no chemotherapy
the cumulative risk of a basal cell carcinoma was 0.7%
(SE=0.4%) by twenty years from three-year survival. One of
the eight, a patient with Gorlin's (basal cell naevus)
syndrome, was genetically predisposed.
In all we observed six-fold the number of malignant SPTs
expected and about twenty-fold the number of malignant
bone tumours expected; four were osteosarcomas arising
within tissue directly irradiated. There were seven malignant
digestive tract tumours observed among all three-year
survivors excluding retinoblastoma, six of these occurring
among those given radiotherapy but not chemotherapy;
within this treatment subgroup this represents fifteen-fold the
number expected. None of these individuals was known to
have genetic conditions predisposing to neoplasia. Further-
more three of these digestive tract SPTs arose within directly
irradiated tissue. Three second primary leukaemias developed
following radiotherapy but no chemotherapy; this represents
five-fold the number expected.
There is no clear systematic variation in relative risk with
increasing follow-up.
Risk of SPT in relation to radiotherapy and chemotherapy
The mean follow-up period following both radiotherapy
and chemotherapy was substantially less than for those with
treatments not involving chemotherapy, Table VII; therefore
our results necessarily apply to this shorter interval. The
cumulative risk of a SPT by ten years from three-year
Table VII Risk of SPT after all FPTs except retinoblastoma - Association with treatment
Mean % with SPT by specified
Treatment follow-up SPT timefrom 3-year survival
group No. period (yrs) No.a (standard error) ob E O/E 95%CI
Neither 1495 9.5 10 1.6% (0.9%) by 10 2.6 3.9 (1.9, 7.1)
RT nor CH 20yrs
RT but no CH 2668 9.8 40 2.7% (0.8%) by 29 5.1 5.6 (3.8, 8.1)
20yrs
Both RT 2699 3.8 11 0.6% (0.7%) by 10 1.1 9.3 (4.5, 17.1)
and CH 10yrs
aTotal number ofSPTs observed; 'Total number of observed SPTs eligible for inclusion in the relative
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survival was under 1%, Table VII. The observed number of
subsequent malignant tumours was about ten-fold expected.
However, this was reduced to four-fold expected with
inclusion of all the possible 'no record' cases. The observed
number of subsequent primary leukaemias was five to ten-
fold expected depending on whether the 'no record' cases
were included or excluded.
SPTs after CNS tumours
The cumulative risk of a SPT by twenty years from three-
year survival is 2.4% (SE=1.1%). However, because of the
occurrence ofmany SPTs after twenty years this rises to 5.1%
(SE=3.7%) by 25 years from three-year survival. Relative
risks of subsequent malignant tumour are reported in Table
VIII; seventeen SPTs were observed, 3.37 expected, yielding
a relative risk of about five. There was a larger than
expected number of both malignant connective tissue and
thyroid tumours.
Table VIII Observed and expected SPTs among three-year
survivors of CNS tumours
TOTAL
No. in group 2,341
Person-years 19,325
Mean follow-up (years) 8.3
SPT (ICD-8) 0 E OIE 95%CI
All sites (140-209) 17 3.37 5.0 (2.9, 8.1)
Digestive (150-159) 2 0.23 8.5 (1.0, 30.8)
Bone (170) 2 0.17 12.0 (1.4, 43.3)
Connective tissue (171) 4 0.10 38.8 (10.6, 99.3)
Breast (174) 0 0.29
Genito-urinary (180-189) 2 0.66 3.1 (0.4, 11.0)
CNS (191-192) 1 0.41 2.4 (0.1, 13.5)
Thyroid (193) 3 0.06 48.7 (10.0, 142.2)
Leukaemia (204-207) 1 0.43 2.3 (0.1, 12.9)
Inherent risk of SPT Among survivors receiving neither
radiotherapy nor chemotherapy the incidence of subsequent
malignant tumours was very similar to that expected, see
Table IX. In fact among these survivors just one SPT was
observed; the individual concerned had neurofibromatosis.
Risk ofSPT in relation to radiotherapy The cumulative risk
of a SPT by twenty years from three-year survival among
those given radiotherapy but no chemotherapy was 4.4%; if
individuals known to be genetically predisposed are excluded
the corresponding figure is 3.2%; see Table IX. Thirteen of
the twenty-one SPTs arose within irradiated tissue, this
includes one leukaemia. Of the eight SPTs developing
outside irradiated tissue, four arose in individuals with
neurofibromatosis. We observed almost nine-fold the number
of subsequent malignant tumours expected. The excess was
reduced to just over six-fold when individuals genetically
predisposed were excluded. A comparison of the cumulative
risk of SPT after neither radiotherapy nor chemotherapy
with that after radiotherapy but no chemotherapy was
significant (P=0.0002 including the genetically predisposed;
P=0.0003 excluding the genetically predisposed). This
provides evidence of radiotherapy being involved in the
development of the excess of SPT observed following CNS
tumours. However, very few three-year survivors of
medulloblastoma or ependymoma had not received radio-
therapy, and therefore the measure of inherent risk is based
almost entirely on survivors of astrocytoma and CNS
tumours other than medulloblastoma and ependymoma.
The four malignant connective tissue tumours observed
following radiotherapy but not chemotherapy all arose in
individuals with neurofibromatosis; also each SPT arose well
outside the volume of tissue directly irradiated to treat the
original CNS tumour. Each of the thyroid carcinomas arose
inside the tissue directly irradiated to treat the original CNS
tumour. Among those treated with radiotherapy but no
chemotherapy the relative risk of a malignant thyroid
tumour was (RR = 108, 95%CI =22, 316).
In summary, there is no evidence of the inherent risk of a
SPT following a CNS tumour being much different from
that expected. However, there is evidence of an increased
absolute and relative risk attributable to treatment by radio-
therapy without chemotherapy, given that a majority of
SPTs developed within tissue directly irradiated, and taking
into account the histological types of SPT, and the intervals
between radiotherapy and diagnosis of the SPTs.
The relative risk of a SPT among these patients is about
ten after a decade from diagnosis and again there is no
evidence of decline in the relative risk with increased survival
time.
SPTs after Wilms' tumour
The cumulative risk of a SPT by 20 years from three-year
survival is 3.1% (SE= 1.9%). The relative risk of a
subsequent malignant tumour was (RR =8, 95%CI =3, 16).
Table IX Risk of SPT after central nervous system tumours - Association with treatment
Mean SPT % with SPT by 20 years
follow-up from 3-yr survival
Treatment No. period (yrs) Site No.a (standard error) ob E OIE 95%CI
Including 578 9.0 all 1 0.7% (0.9%) 1 1.0 1.0 (0.0, 5.6)
genetically
predisposed
Neither SPT cases
RT nor CH Excluding 577 9.0 all 0 0.0% 0
genetically
predisposed
SPT cases
Including 1106 8.0 all 21 4.4% (1.9%) 14 1.6 8.6 (4.7, 14.3)
genetically
predisposed
RT but SPT cases
no CH Excluding 1101 8.0 all 16 3.2% (1.6%) 10 1.6 6.2 (3.0, 11.3)
genetically
predisposed
SPT cases
aTotal number of SPTs observed; "Total number of observed SPTs eligible for inclusion in the relative risk.SECOND PRIMARY TUMOURS AFTER CHILDHOOD CANCER 345
Risk of SPT in relation to radiotherapy Among those given
radiotherapy but no chemotherapy there was a cumulative
risk of SPT of just under 4% by twenty years from three-
year survival. Six of the seven SPTs developed in tissue
directly irradiated. The relative risk of a subsequent
malignant tumour was (RR = 12, 95%CI =4,26) based on an
average follow-up period of over 18 years from three-year
survival.
Considering the histological types of SPT, the period
elapsed after radiotherapy before SPTs appear is at least 13
years, and all SPTs except one arise within tissue irradiated,
we conclude it is likely that radiation is involved in the
development of the excess of SPTs observed.
SPTs after Hodgkin's disease
The cumulative risk of a SPT by ten years from three-year
survival is estimated to be 1.3% (SE=0.6%). The relative
risk of a subsequent malignant tumour was approximately
four; this was significantly larger than one (one-tailed test,
P=0.027), and there was an excess of bone tumours - both
osteosarcomas.
Risk of SPT in relation to radiotherapy Among those
receiving radiotherapy but no chemotherapy the cumulative
risk of a SPT by ten years from three-year survival was
1.5% (SE =0.9%). All four SPTs developed within tissue
directly irradiated. The relative risk of a malignant bone
tumour was (RR=64, 95% CI=8,231) and again the
relative risk of osteosarcoma would be greater.
SPTs after leukaemia
Only three SPTs, all CNS, were observed, though the mean
follow-up period beyond three-years was only 3.4 years. As a
consequence our results following leukaemia are very
provisional. Nevertheless the number of subsequent
malignant CNS tumours observed was about twenty-fold
expected.
Discussion
It is not the purpose of the present study to examine the
relationship between risk of SPT and treatment in detail; this
will be undertaken in a case-control study in which
exhaustive efforts will be made to obtain all treatment
information. However, we examine this relationship in rather
broad terms.
It is very difficult to compare the overall risk from
different series because of the many confounding factors,
including: different series compositions with regard to the
initial childhood cancers, different treatments, different entry
to risk points, different follow-up methods and assumptions
and different average follow-up periods. However, we shall
attempt to compare the overall risks in general terms. In our
series the estimated cumulative probability of SPT by 25
years from three-year survival was about 4%, the relative
risk of a SPT was about six corresponding to an average
follow-up period of about eight years from three-year
survival. The relative and cumulative risks of a SPT were
estimated to be substantially higher in the reports from the
Sidney Farber Cancer Institute (SFCI) series (Li et al., 1975;
Li, 1977): a relative risk of over twenty among five-year
survivors was reported, the cumulative probability of a
second malignancy was estimated to be 12% (SE=4%) by
twenty years from five-year survival; among those who
received orthovoltage radiotherapy the cumulative risk of a
second primary cancer within the radiation field was 17%
(SE =6%) twenty years from five-year survival. The latest
incidence report from the Late Effects Study Group (LESG)
(Tucker et al., 1984) gives a relative risk of fifteen
corresponding to an average follow-up of 5.5 years; the
cumulative risk was estimated to be 12% by 25 years from
diagnosis. Even in the initial report on incidence from LESG
(Mike et al., 1982) where retinoblastoma was specifically
excluded, the risks are no smaller than in our study. The
risks from the University of Minnesota series of children
treated with megavoltage radiotherapy (Potish et al., 1985)
were higher than in our series but they include many benign
tumours that we would exclude from consideration.
The relative risk of SPT remained fairly constant with
time survived in our series, six-fold expected, for the first 30
years following three-year survival after childhood cancer.
There is no evidence of the risk diminishing with increasing
time from diagnosis; this is in agreement with Tucker et al.
(1984).
Radiotherapy was considered to have contributed
substantially towards the excess of second tumours observed
in the LESG, SFCI and the University of Minnesota series.
The increased risk of SPTs in relation to radiotherapy
compared to inherent risk in our study provides evidence
that radiotherapy is involved in the development of some of
the excess of SPTs observed following childhood cancer;
particularly following retinoblastoma and central nervous
system tumours. This interpretation is supported by the
following: the histological types of SPTs observed; the
proportion of SPTs developing within tissue directly
irradiated to treat the FPT; the intervals between radio-
therapy and diagnosis of the SPTs.
Although there is substantial evidence from these studies
of a relationship between radiotherapy and an increased risk
of SPTs there is comparatively little evidence available on
the risk associated with chemotherapy given to treat cancer
in children. At present, within our cohort the average
follow-up times beyond three years are short following
chemotherapy except among retinoblastoma survivors.
However, some indication of what may emerge in future
analyses may be obtained from the accompanying paper
(Kingston et al., 1987), since this contains cases excluded
from the cohort analysis because either the FPT or SPT
occurred too recently for inclusion. We note here only that
there is evidence that types of FPT and SPT observed appear
to be changing, in that among individuals with their FPT
diagnosed since 1970 the number of survivors subsequently
developing leukaemia has increased substantially, the
increase being spread across several FPT types including
central nervous system tumours, acute leukaemia and
lymphoma. This period corresponds to the increasing use of
intensive multiple agent chemotherapy and it is tempting to
consider chemotherapy as a cause. This might be indirect
for instance as a result of immunosuppression, or because
chemotherapy provided sufficient survival time for SPTs to
emerge as a result of a mechanism not directly involving the
chemotherapy, for example inherent predisposition (Penn,
1982).
A recent paper by the LESG (Tucker et al., 1985a) reports
an excess of second primary leukaemia within a cohort of
individuals surviving at least two years from diagnosis of
childhood cancer (0=22, E= 1.52, O/E= 14, 95%CI=(9,
22)). To determine if the increased risk was related to
therapy a case-control study was carried out. No increase in
risk was associated with radiotherapy. However, there was a
significant relationship between dose of alkylating agents and
the relative risk of secondary leukaemia, the relative risk
reaching about twenty for the high (alkylating agent) dose
categories. They conclude that the excess risk of secondary
leukaemia following childhood cancer was almost entirely
due to alkylating agents.
Genetic predisposition to multiple primary tumours exists
among the survivors of genetic retinoblastoma, and the
individuals with neurofibromatosis or Gorlin's (basal cell
naevus) syndrome who developed a FPT of the central
nervous system followed by a variety of SPTs. Among the
survivors of genetic retinoblastoma there was an inherent
risk of SPTs about thirteen-fold that expected from general
population rates of cancer; the inherent risk of osteosarcoma346 M.M. HAWKINS et al.
exceeding 174-fold expected. After all first primary tumours
except retinoblastoma, considered as one group, there was
an inherent risk of a subsequent malignant tumour about
four-fold expected.
Secondprimary tumoursfollowing retinoblastoma
In our study the overall relative risk of a SPT was about 30
following genetic retinoblastoma, observed malignant bone
tumours being more than 400-fold expected. There was
evidence of an increased risk of SPT generally and
osteosarcomas in particular following radiotherapy for
genetic retinoblastoma compared to the inherent risk. There
is some evidence of an increased risk of SPT associated with
the use of cyclophosphamide, though it is not possible to be
sure whether this is due to cyclophosphamide alone or
radiotherapy or an interaction between them.
From a series of individuals on file at the Ophthalmic
Oncology Center of the New York Hospital, Cornell
Medical Center, a report (Abramson et al., 1984) gives risks
of 20%, 50% and 90% at 10, 20 and 30 years from
diagnosis of genetic retinoblastoma respectively; also
reported are risks of second tumours in patients treated
without radiotherapy or where tumours developed outside
the radiation field of 10%, 30% and 68% at 10, 20 and 32
years from diagnosis respectively. These cumulative risks are
an order of magnitude greater than estimated from our
series, and it is very hard to explain the large discrepancy.
However, we are satisfied that we have not missed a
substantial number of SPTs within our cohort. Another large
series is part of the LESG report (Tucker et al., 1984), where
319 two-year survivors of retinoblastoma have been
followed-up for an average period of seven years. No
separation of unilateral and bilateral cases was carried out;
the overall relative risk of a second primary was about 60;
bone tumours were 1,000-fold expected.
Secondprimary bone tumoursfollowing childhood cancer other
than retinoblastoma
After all first primary tumours except retinoblastoma,
considered as one group, the number of malignant bone
tumours observed was eighteen-fold expected. Eight were
osteosarcomas, one a fibrosarcoma and one an unspecified
malignant tumour. Six of the bone tumours arose within
directly irradiated tissue. The LESG has reported results from
a case-control study of the involvement of radiotherapy and
chemotherapy in the development of second primary bone
cancer following childhood cancer (Tucker et al., 1985b). In
both retinoblastoma and other patients, the relative risk
increased with increasing radiation dose, reaching a value of
almost 40 at doses over 50Gy. Independently of radio-
therapy, alkylating agents were associated with a significant
two-fold risk of bone cancer in both retinoblastoma and
other patients.
Secondprimary CNS tumoursfollowing childhood cancer
other than retinoblastoma
The number of second primary malignant CNS tumours
observed was about seven-fold expected. The presence of an
increased inherent risk among survivors of childhood cancer
is in line with the report of an increased likelihood of CNS
tumours, leukaemia, and childhood tumours in relatives of
children with CNS neoplasms (Farwell & Flannery, 1984b).
Several familial cancer syndromes have been reported
involving tumours of the CNS; two, Turcot's syndrome
(Turcot et al., 1959; Todd et al., 1981) and the Li-Fraumeni
syndrome (Li & Fraumeni, 1969; Li & Fraumeni, 1982;
Birch et al., 1984), are well documented. Meadows et al.
(1977) have suggested that the frequency of CNS tumours
with leukaemia in their series may indicate a hereditary
cancer syndrome.
Basal cell carcinomafollowing childhood cancer other than
retinoblastoma
Eight basal cell carcinomas were observed following a
variety of FPTs, all within tissue directly irradiated to treat
the FPT; one individual was known to have Gorlin's (basal
cell naevus) syndrome; all but one of the cases occurred
more than a decade from radiotherapy, all evidence
consistent with the involvement of radiation. Previous
reports have implicated radiotherapy in the development of
skin carcinomas following childhood cancer, notably
Meadows et al. (1985).
SPTsfollowing CNS tumours
Given the evidence of a familial element in cancer occurring
in some families with a child with CNS tumour, it would not
have been surprising to have identified an increased inherent
risk of SPT above that expected. However, there was no
evidence from our series of a substantially increased inherent
risk of SPT among survivors of a CNS tumour. Of course
we cannot exclude the possibility of there being a small
excess inherent risk not detectable with current numbers of
tumours. From our cohort there is convincing prima facie
evidence that radiotherapy is involved in the development of
an excess of subsequent malignant tumours following a CNS
tumour, six to nine-fold expected depending on whether
genetically predisposed cases are included or excluded. As
might have been anticipated from previous work (Shore et
al., 1984; Ron & Modan, 1984) there was an excess of
thyroid cancer, 100-fold expected among those treated with
radiotherapy but no chemotherapy.
In a series of 670 individuals diagnosed with a CNS
neoplasm before age twenty, nine had another primary
neoplasm either before or after the CNS primary (Farwell &
Flannery. 1984a). The expected number of neoplasms was
0.99, yielding a relative risk of about nine. Radiotherapy was
identified as a possible contributing factor to the develop-
ment of the SPT in four individuals.
SPTs after Wilms' tumour
The LESG (Tucker et al., 1984) examined the observed and
expected numbers of second primary cancers among 1,248
children surviving at least two years from diagnosis of
Wilms' tumour: the relative risk of any subsequent cancer
was 24. Relative risks were significantly raised for thyroid,
bone, connective tissue, digestive tract, CNS and leukaemia.
Another large study of survivors of Wilms' tumour (Li et
al., 1983), was based on 487 individuals treated at the Dana-
Farber Cancer Institute and Children's Hospital of Boston.
Thirty SPTs were observed: eleven malignant, sixteen benign
and three border line neoplasms. The cumulative risk of a
second tumour was 6% (SE=2%) by twenty years from
diagnosis. All but one second malignant tumour arose within
the prior radiotherapy field. Of the benign second tumours
nine were within the radiotherapy field. Among those given
radiotherapy the relative risk of a second cancer was
fourteen.
The results from the Dana-Farber series are similar to
those from our series, though the risks from the LESG series
are much larger.
SPTs after leukaemia
No firm conclusions may yet be drawn concerning the SPT
risk following leukaemia in our series, since the average
follow-up period beyond three-year survival is only just over
three years. The twenty-fold excess of CNS tumours is quite
striking, though it is based on only three cases. These all
arose in individuals treated with chemotherapy and CNS
irradiation; we cannot infer that treatment was necessarily
directly involved in their development, since we have no
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Conclusion
The rate of occurrence of SPT is low and the risk
attributable to therapy is small when compared to the
improvements in survival rates achieved by the use of these
treatments. Our data confirm that the use of radiotherapy is
associated with an increased risk of SPT. However, the risks
of SPT in our data are almost always lower than those
reported from series treated in the United States. It is
possible that the lower frequency of SPT observed in our
data may be accounted for, to some extent, by the use of
less combination therapy and lower doses of radiotherapy in
Britain. It is our intention to explore these international
differences further in the future. It is important to continue
to monitor survivors so that tumour and treatment
combinations giving rise to particularly excessive frequencies
of SPTs may be identified and alternative therapies examined
to see whether comparable survivla may be achieved with
reduced adverse late effects.
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